Loading...
XNASCLGN
Market cap40mUSD
Dec 24, Last price  
3.50USD
1D
1.74%
1Q
-26.81%
Name

Collplant Biotechnologies Ltd

Chart & Performance

D1W1MN
XNAS:CLGN chart
P/E
—
P/S
3.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.04%
Rev. gr., 5y
18.01%
Revenues
11m
+3,565.22%
000075,911479,9174,788,3802,318,0006,137,00015,641,000299,00010,959,000
Net income
-7m
L-58.10%
-4,601,601-4,749,682-3,342,401-4,786,346-7,239,669-6,051,000-6,249,000-14,697,000-5,808,000409,000-16,753,000-7,019,000
CFO
-3m
L-79.83%
0000000-5,703,000-4,451,0002,501,000-13,698,000-2,763,000
Earnings
Apr 02, 2025

Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
URL
https://www.collplant.com/
IPO date
Sep 01, 1993
Employees
73
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
10,959
3,565.22%
299
-98.09%
15,641
154.86%
Cost of revenue
12,475
10,655
9,636
Unusual Expense (Income)
NOPBT
(1,516)
(10,356)
6,005
NOPBT Margin
38.39%
Operating Taxes
(172)
(172)
Tax Rate
NOPAT
(1,516)
(10,184)
6,177
Net income
(7,019)
-58.10%
(16,753)
-4,196.09%
409
-107.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,108
1,874
32,743
BB yield
-1.52%
-2.03%
-16.72%
Debt
Debt current
624
529
519
Long-term debt
5,694
5,293
6,697
Deferred revenue
Other long-term liabilities
Net debt
(20,356)
(24,019)
(36,296)
Cash flow
Cash from operating activities
(2,763)
(13,698)
2,501
CAPEX
(954)
(1,316)
(1,589)
Cash from investing activities
(1,156)
28,922
(31,556)
Cash from financing activities
1,108
1,874
38,760
FCF
(1,698)
(10,180)
5,398
Balance
Cash
26,674
29,653
43,299
Long term investments
188
213
Excess cash
26,126
29,826
42,730
Stockholders' equity
(92,728)
(85,818)
(69,102)
Invested Capital
124,227
121,010
117,831
ROIC
6.28%
ROCE
12.32%
EV
Common stock shares outstanding
11,389
11,033
11,967
Price
6.39
-23.47%
8.35
-48.96%
16.36
51.90%
Market cap
72,777
-21.00%
92,128
-52.94%
195,777
163.95%
EV
52,421
68,109
159,481
EBITDA
(414)
(9,280)
6,778
EV/EBITDA
23.53
Interest
10
172
37
Interest/NOPBT
0.62%